Zobrazeno 1 - 10
of 28
pro vyhledávání: '"Adham S Bear"'
Autor:
Adham S Bear, Laura C Kennedy, Joseph K Young, Serena K Perna, Joao Paulo Mattos Almeida, Adam Y Lin, Phillip C Eckels, Rebekah A Drezek, Aaron E Foster
Publikováno v:
PLoS ONE, Vol 8, Iss 7, p e69073 (2013)
Ablative treatments such as photothermal therapy (PTT) are attractive anticancer strategies because they debulk accessible tumor sites while simultaneously priming antitumor immune responses. However, the immune response following thermal ablation is
Externí odkaz:
https://doaj.org/article/5669772c71314b089987371bba19e559
Autor:
Adham S. Bear, Tatiana Blanchard, Joseph Cesare, Michael J. Ford, Lee P. Richman, Chong Xu, Miren L. Baroja, Sarah McCuaig, Christina Costeas, Khatuna Gabunia, John Scholler, Avery D. Posey, Mark H. O’Hara, Anze Smole, Daniel J. Powell, Benjamin A. Garcia, Robert H. Vonderheide, Gerald P. Linette, Beatriz M. Carreno
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-16 (2021)
KRAS is commonly mutated at codon 12 in several cancer types, offering a unique opportunity for the development of neoantigen-targeted immunotherapy. Here the authors present a pipeline for the prediction, identification and validation of HLA class-I
Externí odkaz:
https://doaj.org/article/5c32458bd77b40989a4cd89c57021223
Autor:
Robert H. Vonderheide, Adham S. Bear
Publikováno v:
Frontiers in Immunology, Vol 11 (2020)
Like many tumor types, pancreatic ductal adenocarcinoma (PDAC) exhibits a rich network of tumor-derived cytokines and chemokines that drive recruitment of myeloid cells to the tumor microenvironment (TME). These cells, which include tumor-associated
Externí odkaz:
https://doaj.org/article/df56915ac00e41c5a7e766fe1adef617
Publikováno v:
American Society of Clinical Oncology Educational Book. :57-65
Cancer immunotherapy tools include antibodies, vaccines, cytokines, oncolytic viruses, bispecific molecules, and cellular therapies. This review will focus on adoptive cellular therapy, which involves the isolation of a patient’s own immune cells f
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6d2ddd3bcd1d270fb99fe12fc91ab4fa
https://doi.org/10.1200/edbk_321115
https://doi.org/10.1200/edbk_321115
Autor:
Adham S. Bear, Rebecca B. Nadler, John Scholler, Robert H. Vonderheide, Gerald P. Linette, Beatriz M. Carreno
Publikováno v:
Molecular Cancer Research. 21:PR08-PR08
Background: KRAS mutations drive tumorigenesis in adenocarcinomas of the lung (30-40%), colon (40-50%) and pancreas (>90%). Recent clinical evidence demonstrates potent and durable anti-tumor activity of adoptively transferred KRAS-specific T cells i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::69a92e5aa292eef0e3a7accc39a32a7f
https://doi.org/10.1158/1557-3125.ras23-pr08
https://doi.org/10.1158/1557-3125.ras23-pr08
Publikováno v:
Cancer Cell
Summary Pancreatic ductal adenocarcinoma (PDA) is among the most immune-resistant tumor types. Its unique genomic landscape shaped by oncogenic drivers promotes immune suppression from the earliest stages of tumor inception to subvert adaptive T cell
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::99095d4552bc3cf22e9aad1a801d43c7
https://doi.org/10.1016/j.ccell.2020.08.004
https://doi.org/10.1016/j.ccell.2020.08.004
Autor:
Mark H. O'Hara, Adham S. Bear, Max M. Wattenberg, Ursina R. Teitelbaum, Kim A. Reiss, Thomas B. Karasic, Charles J. Schneider, Peter J. O'Dwyer, Edgar H. Ben-Josef, Andrzej P. Wojcieszynski, Amit H. Maity, Rosemarie H. Mick, Robert H. Vonderheide
Publikováno v:
Cancer Research. 82:A016-A016
Immune checkpoint inhibitors have limited clinical activity in pancreatic cancer. Based on preclinical data, we hypothesized that hypofractionated radiation may cooperate with dual checkpoint inhibition in patients (Rech AJ, et al, Cancer Research, 2
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0866eb77debc46444121d6f8806b5bb2
https://doi.org/10.1158/1538-7445.panca22-a016
https://doi.org/10.1158/1538-7445.panca22-a016
Autor:
Stuti Shroff, Major K. Lee, James M. Metz, Edgar Ben-Josef, Ursina R. Teitelbaum, Kim A. Reiss, William Tristram Arscott, Kevin T. Nead, Mark H. O'Hara, John N. Lukens, Andrzej P. Wojcieszynski, Jacob E. Shabason, Jeffrey A. Drebin, Sriram Venigalla, Adham S. Bear, John P. Plastaras, Arturo Loaiza-Bonilla
Publikováno v:
American Journal of Clinical Oncology
Purpose: This study evaluates the toxicity and tumor response with concurrent nab-paclitaxel chemoradiotherapy (CRT) compared with standard (5-fluorouracil or gemcitabine) CRT. Materials and Methods: Fifty patients with borderline resectable or unres
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::65e8550b9eef23f792c2aefeb1fcf0f3
https://pubmed.ncbi.nlm.nih.gov/34310350
https://pubmed.ncbi.nlm.nih.gov/34310350
Autor:
Mark H. O'Hara, Chong Xu, Adham S. Bear, Benjamin A. Garcia, Robert H. Vonderheide, Beatriz M. Carreno, Khatuna Gabunia, Christina Costeas, John Scholler, Avery D. Posey, Michael J. Ford, Sarah McCuaig, Tatiana Blanchard, Smole Anze, Gerald P. Linette, Daniel J. Powell, Miren L. Baroja, Joseph Cesare, Lee P. Richman
Publikováno v:
Nature Communications
Nature Communications, Vol 12, Iss 1, Pp 1-16 (2021)
Nature Communications, Vol 12, Iss 1, Pp 1-16 (2021)
Activating RAS missense mutations are among the most prevalent genomic alterations observed in human cancers and drive oncogenesis in the three most lethal tumor types. Emerging evidence suggests mutant KRAS (mKRAS) may be targeted immunologically, b
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e1d448873337c12f6e81ff892eeb01b5
http://europepmc.org/articles/PMC8285372
http://europepmc.org/articles/PMC8285372
Autor:
Anže Smole, Alexander Benton, Mathilde A. Poussin, Monika A. Eiva, Claudia Mezzanotte, Barbara Camisa, Beatrice Greco, Prannda Sharma, Nicholas G. Minutolo, Falon Gray, Adham S. Bear, Miren L. Baroja, Casey Cummins, Chong Xu, Francesca Sanvito, Andrea Lang Goldgewicht, Tatiana Blanchard, Alba Rodriguez-Garcia, Michael Klichinsky, Chiara Bonini, Carl H. June, Avery D. Posey, Gerald P. Linette, Beatriz M. Carreno, Monica Casucci, Daniel J. Powell
Publikováno v:
Cancer cell. 40(12)
Despite the success of CAR-T cell cancer immunotherapy, challenges in efficacy and safety remain. Investigators have begun to enhance CAR-T cells with the expression of accessory molecules to address these challenges. Current systems rely on constitu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::edb9f2ad9372341858381e556b04b329
https://pubmed.ncbi.nlm.nih.gov/36513049
https://pubmed.ncbi.nlm.nih.gov/36513049